Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Oil Prices Rebound as U.S.-Venezuela Tensions Offset Oversupply Concerns 
China’s November Economic Data Signals Slowing Industrial Output and Weak Consumer Demand 
Indonesia–U.S. Tariff Talks Near Completion as Both Sides Push for Year-End Deal 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
China’s Small Bank Consolidation Struggles as Profits Fall and Risks Persist 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Oil Prices Rebound in Asia as Venezuela Sanctions Risks Offset Ukraine Peace Hopes 
Asian Technology and Chipmaking Stocks Slide as AI Spending Concerns Shake Markets 
U.S. Dollar Slides for Third Straight Week as Rate Cut Expectations Boost Euro and Pound 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
ASX Shares Slide After ASIC Imposes A$150 Million Capital Requirement 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Samsung Biologics and Novartis International AG signed a contract manufacturing organization deal, and this was announced on Tuesday, June 7. The deal is worth $81 million.
According to The Korea Herald, the South Korean biotech company signed an intent letter for the CMO with the Swiss multinational pharmaceutical corporation. The agreement was announced via Samsung Biologics’ regulatory filing that also revealed that the companies signed the initial contract late last week.
Based on the report, the amount of the contract is equivalent to 6.41% of Samsung Biologics’ annual sales last year, which reached KRW1.57 trillion or around $1.25 billion. Then again, it was not mentioned which of Novartis’ biopharmaceutical products Samsung Biologics is producing under the CMO agreement.
The Korean biotech firm said that it would be releasing more deals in the future after both parties signed the main contract for their CMO partnership. The collab is said to be the first time Samsung Biologics is securing a deal from the Swiss pharmaceutical company.
“The letter of intent was the first contract between the two firms,” an official of Samsung Biologics stated. “We look forward to continuing to have cooperative relations through this deal in the future.”
The Korea Economic Daily reported that the latest deal increased Samsung Biologics’ total for CMO contracts to $400 million. The company has so far won orders from other multinational pharma firms such as GSK plc that is formerly known as GlaxoSmithKline plc, and Eli Lilly & Co. this year. In comparison, the firm was able to secure $1 billion worth of CMO contracts in 2021.
The South Korean CMO drugmaker obtained contracts from the top pharmaceutical firms in the world, including Bristol Myers Squibb, Roche, Johnson & Johnson, and Merck & Co. It was added that Samsung Biologics also has a contract with Gilead Sciences Inc. in the US.
Meanwhile, Samsung Biologics has been mostly manufacturing antibody treatments recently instead of cell-gene therapy (CGT). It has built up production facilities to make the drug substance for the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines in its plant.
